Clinical Study

A071702 A Phase II Study Of Checkpoint Blockade Immunotherapy In Patients With Somatically Hypermutated Recurrent Glioblastoma

Posted Date: May 24, 2021

  • Investigator: Soma Sengupta
  • Specialties: Cancer, Neurology, Oncology
  • Type of Study: Drug

The primary objective of this study is to determine whether the combination of ipilimumab and nivolumab increases the tumor response rate assessed by modified Response Assessment in Neuro-Oncology (RANO) Criteria in patients with hypermutated recurrent glioblastoma. Efficacy will be determined by measuring overall response rate.


Histologically Confirmed Glioblastoma, Presence Of Measurable Disease Prior To Resection Or Biopsy Of Recurrent Tumor, Ecog Score Of 0-2, No Active Autoimmune Disease Or History Of Autoimmune Disease, No Prior Treatment With Checkpoint Blockade Therapies (Anti-Ctla4, Anti-Pd1/Pd-L1) Or Bevacizumab


Glioblastoma, Brain, Neuro-Oncology

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.